Table 2.

Percentage of Vaccinated Subjects with Antibodies Against Vaccinia Proteins

> 75% of subjects	50–75% of subjects	25–50% of subjects	< 25% of subjects
A13L	A12L	A10L	A14.5L	B1R	F4L	WR002
A14L	A19L	A11R	A15L	B2R	F5L	WR003
A27L	A4L	A12L	A17L	B3R	F6L	WR004
A40R	A9L	A16L	A18R	B4R	F8L	WR005
A56R	B20R	A22R	A1L	B5R	F9L	WR006
C5L	D8L	A36R	A20R	B6R	G1L	WR007
D13L	E3L	A42R	A21L	B7R	G2R	WR008
H5R	E4L	A43R	A23R	B8R	G3L	WR009
I1L	F7L	A49R	A24R	C12L	G5R	WR010
WR001	H3L	A50R	A25L	C14L	G8R	WR011
WR146	H6R	A52R	A28L	C1L	G9R	WR012
WR148	J1R	B15R	A29L	C2L	H1L	WR013
WR218	N1L	B16R	A2L	C4L	H2R	WR014
	WR169	B17L	A30L	C6L	H4L	WR015
	WR214	B19R	A31R	C7L	H7R	WR016
		B9R	A32L	C8L	I2L	WR018
		C17L	A33R	D10R	I3L	WR019
		C3L	A34R	D11L	I4L	WR053.5
		E1L	A35R	D12L	I5L	WR083
		E5R	A37R	D1R	I7L	WR121
		E9L	A38L	D2L	I8R	WR149
		F11L	A3L	D3R	J2R	WR153.5
		F13L	A41L	D4R	J3R	WR161
		F14L	A44L	D5R	J4R	WR163
		F17R	A45R	D6R	J5L	WR164
		G4L	A46R	D7R	J6R	WR181.5
		G6R	A47L	D9R	K1L	WR199
		G7L	A48R	E10R	K3L	WR201
		I6L	A51R	E11L	K4L	WR204
		J1R	A53R	E2L	K5L	WR204.5
		K2L	A55R	E6R	K6L	WR204f
		L4R	A57R	E7R	K7R	WR207
		L5R	A5R	E8R	L1R	WR209
		WR036	A6L	F10L	L2R	WR210
		WR147	A7L	F12L	L3L	WR211
		WR203	A8R	F15L	M1L	WR212
		WR208	B10R	F16L	M2L	WR213
		WR220	B11R	F1L	N2L	WR215
			B12R	F2L	O1L	WR216
			B14R	F3L	O2L	WR217